



FOR IMMEDIATE RELEASE

PPD Recognized for Excellence in Clinical Research in CRO Leadership Awards

Pharmaceutical and biotech executives cite PPD for capabilities and reliability

WILMINGTON, N.C., (May 9, 2018) – Pharmaceutical Product Development, LLC ([PPD](#)) today announced it has been recognized for excellence in clinical research by pharmaceutical and biotechnology executives surveyed for [Life Science Leader](#) magazine's 2018 [CRO Leadership Awards](#).

PPD earned honors for its capabilities and reliability, based on survey responses from industry executives responsible for making or influencing decisions to outsource [clinical development](#) programs to a contract research organization (CRO).

PPD is recognized as a leader in the CRO industry based on its reputation for operational delivery, with comprehensive services ranging from early development to all phases of clinical development, peri- and post-approval services and comprehensive and integrated laboratory services through PPD® Laboratories.

“PPD’s distinctive culture reflects our commitment to earning our clients’ trust by demonstrating quality delivery, integrity and a shared dedication to delivering life-changing therapies to improve health,” said David Simmons, chairman and CEO of PPD. “This industry recognition, mirroring the confidence of biopharmaceutical and biotechnology leaders in PPD, speaks to the high caliber of our global team of talented employees. They bring extraordinary expertise, a strong collaborative work ethic and an unrivaled passion for supporting client success.”

The survey for the 2018 CRO Leadership Awards, which encompassed 27 performance metrics, was conducted by Industry Standard Research, a full-service pharmaceutical market research firm, to help *Life Science Leader* assess the performance of CROs.

About PPD

PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 47 countries and approximately 20,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health. For more information, visit www.ppd.com.

PPD Contacts

Media:
Randy Buckwalter
+1 919 456 4425
randy.buckwalter@ppdi.com

Investors:
Nate Speicher
+1 910 558 6783
nate.speicher@ppdi.com

###